Fludarabine and Cytarabine combination

The combination of fludarabine and cytarabine is a chemotherapy regimen primarily used in the treatment of acute myeloid leukemia (AML) and other hematological malignancies. This combination has shown significant efficacy, particularly in relapsed or refractory cases. ## Pharmacological Mechanism Fludarabine potentiates the metabolism of cytarabine in a synergistic manner. When fludarabine is administered before cytarabine, it increases the accumulation of ara-C triphosphate (ara-CTP), which is the active metabolite of cytarabine, in leukemia cells[1]. Studies have shown that fludarabine infusion before cytarabine can increase the area under the curve (AUC) of ara-CTP by approximately 1.8-fold and enhance the rate of ara-CTP accumulation by about 2.0-fold[1]. The optimal timing appears to be administering cytarabine approximately 4 hours after fludarabine infusion, which maximizes the synergistic effect[6][8]. This pharmacological interaction allows for potentially more effective treatment with lower toxicity compared to high-dose cytarabine alone. ## Clinical Applications The fludarabine + cytarabine combination is used in several clinical contexts: 1. **Salvage therapy** for relapsed or refractory AML 2. **Consolidation therapy** as an alternative to high-dose cytarabine 3. **Induction therapy** for newly diagnosed AML patients 4. **Treatment for high-risk myelodysplastic syndrome (MDS)** This combination is often incorporated into regimens such as: - **FLAG** (Fludarabine, Cytarabine, and G-CSF/Filgrastim)[6][8] - **FLAG-Ida** (Fludarabine, Cytarabine, Idarubicin, and G-CSF)[2] - **FCE** (Fludarabine, Cytarabine, and Etoposide)[7] ## Dosing Regimens Standard dosing for the fludarabine + cytarabine combination typically includes: - **Fludarabine**: 30 mg/m² IV infusion daily for 3-5 days - **Cytarabine**: 1,000-2,000 mg/m² IV infusion daily for 3-5 days[5][6][8] For older patients (>60 years), the cytarabine dose may be reduced to 1,000 mg/m² to minimize toxicity[8]. ## Efficacy The combination has demonstrated promising efficacy: - In relapsed/refractory AML, complete remission (CR) rates of 14-75% have been reported, depending on patient characteristics and prior treatments[3][7] - For patients with de novo AML, CR rates of approximately 47% have been observed[3] - For patients with a first complete remission duration ≥12 months, CR rates of about 64% have been reported[3] ## Safety Profile The fludarabine + cytarabine combination is generally well-tolerated compared to other intensive chemotherapy regimens. Common adverse effects include: - Myelosuppression (neutropenia, thrombocytopenia, anemia) - Infections - Cytarabine syndrome (flu-like symptoms, skin rash, occasionally chest pain) - Neurotoxicity (particularly with high-dose cytarabine) Treatment-related mortality rates are relatively low, with 4-week mortality rates of approximately 13% reported in some studies[3]. ## Ongoing Research The combination is being studied in various clinical trials, including in combination with newer agents such as selinexor (KPT-330) for refractory or relapsed leukemia or myelodysplastic syndrome[4]. The fludarabine + cytarabine combination represents an important treatment option in the management of acute myeloid leukemia and related hematological malignancies, offering a balance of efficacy and tolerability for patients who may not tolerate more intensive regimens.

Brand names

FludaraCytosar-U

Other names

fludarabine and cytarabineAra-C and fludarabinefludarabine phosphate + cytarabine